What one share of Neumora Therapeutics holds
We are a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by bringing forward the next generation of novel therapies with brain-penetrant chemistry that offer improved treatment outcomes and quality of life for patients.
Neumora Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.22 |
|---|---|
| Cash and investments | $0.62 |
| Debt | $0.60 |
| Book value | $0.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$4.81 | $0.02 | −$4.24 | — | −$13.70 |
| 2023 | — | −$3.63 | $0.00 | −$2.51 | — | — |
| 2024 | — | −$1.53 | — | — | — | $1.78 |
| 2025 | — | −$1.45 | — | — | — | $0.60 |
Common questions about Neumora Therapeutics
How much does one share of Neumora Therapeutics earn?
Over the last 12 months, Neumora Therapeutics lost $1.22 for each share.
Does Neumora Therapeutics pay a dividend?
Neumora Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Neumora Therapeutics’s book value per share?
Neumora Therapeutics’s book value is $0.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Neumora Therapeutics have?
Each share of Neumora Therapeutics has $0.62 of cash and investments and $0.60 of debt, as of June 30, 2026.
Has Neumora Therapeutics bought back shares?
Neumora Therapeutics’s share count rose about 501% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.